Inversions in the pharmaceutical sector could become less lucrative as a result of new tax laws.
New tax rules were introduced on Sept. 29, 2014 by the United States Treasury Department with the purpose of discouraging companies to avoid taxation by merging with foreign companies in another fiscal jurisdiction. This practice of tax inversion has been a significant driver of merger and acquisition (M&A) activity in the pharmaceutical and life-sciences sector, and the curbing of this technique may slow M&A activity, reports Burrill Media.
The new changes will make it more difficult for US companies to benefit from moving a business overseas, where corporate taxes are lower. Specifically, the rules will restrict the ability of US companies to access overseas profits to fund acquisitions without paying US taxes and will also limit the level of ownership the US owners can have in an inverted company.
Inversion deals that were formerly based on tax savings alone will now have to be based on other synergies. However, the new rules will merely slow, not halt, M&A deals in the pharmaceutical sector, notes G. Steven Burrill, CEO of Burrill Media. “When the new session of Congress begins, the controversy over inversions represents an opportunity for comprehensive tax reform and the opportunity to address substantive tax issues of concern to the industry from the effects of tax policy on investment to its ability to incentivize R&D spending.”
SOURCE:
Burrill Media
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.